Amlodipine Besylate

Amlodipine Besylate

Amlodipine, sold under the brand name Norvasc, is an oral voltage-dependent L-type calcium channel blocker with the chemical constitution of dihydropyridine. It was initially approved in 1987 by the U.S. Food and Drug Administration. Amlodipine blocks the initial entry of calcium and has the longest half-life of 30 to 50 hours compared to other drugs of similar category. Amlodipine besylate is generally used to treat heart disorders, including high blood pressure and chronic stable angina. Amlodipine besylate is gaining prominence in the market owing to increasing cardiovascular diseases and genetic disorders, rising cases of obesity, and rising demand for oral drugs. For instance, the Consensus of the Taiwan Society of Cardiology in May 2023 reported a prevalence of around 1-2% of heart failure in adults. The Centers for Disease Control and Prevention of the U.S. estimated that approximately 0.8 million people in the U.S. suffer from a heart attack every year in May 2023. Several factors, including a surge in the increasing awareness regarding cardiovascular diseases, increasing geriatric population, increasing smoking population, rising alcoholism culture, the surge in the adoption of combination therapies, and increased investments from the government, public, and private sectors in cardiovascular departments are driving the growth of the market during the forecast period. According to the World Health Organization (WHO), the share of people aged above 60 will rise to 1.4 billion by 2030 while this share will increase to 2.1 billion by 2050 which would be more than double the share of the geriatric population in the year 2020 i.e., 1 billion.

The Amlodipine Besylate Market is expected to grow at a steady rate of around 4.5% owing to the increased prevalence of cardiovascular diseases globally due to prevalent unhealthy lifestyles which are directly responsible for obesity. For instance, as per the World Obesity Atlas 2022, estimations are such that 1 billion people worldwide, comprising one in five women and one in seven men will be suffering from obesity by the year 2030. Many new therapies are being introduced for treating these cardiovascular diseases including a combination of treatments, immunotherapy, and many more. Several other factors, such as rising genetic disorders, and increasing prevalence of hypertension among people are also driving this market of amlodipine besylate at a steady rate. For instance, in July 2023, the Centers for Disease Control and Prevention (CDC) reported that nearly half of adults had hypertension i.e., systolic blood pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg in 2021.

• Based on dosage type, the market is segmented into 2.5 mg, 5 mg, and 10 mg. The 10 mg segment held the maximum share in the global market of amlodipine besylate in 2022. This segment dominated the market because of the rising demand for oral drugs among patients. Also, the increased prevalence of ill lifestyles including smoking, alcoholism, and unhealthy diets is boosting this segment’s growth. According to a recent report by the FDA in January 2021, there were significant increases in exercise time (bicycle or treadmill) in patients with chronic stable angina and decreased angina attack rate when administered with the 10 mg dose of NORVASC( Amlodipine Besylate). Hence, due to the above reasons, the 10 mg segment held a significant share of the market in 2022.
• Based on application, the market is categorized into high blood pressure and heart diseases. The high blood pressure segment is expected to hold a significant share of the market in the forecast period owing to the prevalent ill lifestyle of people, including an adaption of smoking and alcohol. For instance, according to the Journal of the American Heart Association in January 2022, the prevalence of cigarette use in the past 30 days among middle and high school students in the U.S. was 1.6% and 4.6%, respectively, in 2020. Apart from this, rising obesity and geriatric population are also impelling the growth of this segment. Hence, amongst applications, the high blood pressure category is expected to witness higher CAGR during the forecast period.
• For a better understanding of the market adoption of amlodipine besylate, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the global amlodipine besylate market in the year 2022 due to the increasing cardiovascular disorders, increasing alcohol consumption, and rising number of investments in developing effective therapeutics. Government organizations are initiating cardiovascular awareness programs to provide efficient care to patients. For instance, according to the American Journal of Managed Care pulmonary arterial hypertension is a rare disorder found in 15 to 50 persons per million within the U.S. and Europe. Also, according to the National Institute of Health, the mean prevalence of pulmonary arterial hypertension was 11.6 per million and the approximate incidence rate was 2.4 per million children per year in June 2020. Thus, North America held a significant share of the market in the year 2022.
• Some of the major players operating in the market include Alkem Laboratories Ltd.; Mylan Inc.; Dr. Reddy's Laboratories Ltd.; Macleods Pharmaceuticals Ltd.; Lupin; Aurobindo Pharma; Pfizer Inc.; Cipla Inc.; Sun Pharmaceutical Industries Ltd.; Wockhardt.